A group of medical advisors have told U.S. regulators that the world's best-selling prescription arthritis drug, Celebrex, should stay on the market but with a warning about side-effects.

The discussion follows a study in December that showed Celebrex raises the risk of heart problems for some patients.

The World's Best-selling Arthritis Drug Gets a Vote of Confidence and a Warning Label

But the advisory group decided that the benefits of the drug outweigh the potential harm.

The World's Best-selling Arthritis Drug Gets a Vote of Confidence and a Warning Label

The panel also said that another drug from the Pfizer company, Bextra, also raises heart concerns but should also stay on the market.

The World's Best-selling Arthritis Drug Gets a Vote of Confidence and a Warning Label

Pfizer sold $3.3 billion worth of Celebrex last year.

The U.S. Food and Drug Administration will make a final decision on the future of the drug, but the regulators generally follow suggestions from their scientific advisors.